2024-05-31-accounts - Haemstar: Haematology Specialty Training Audit And Research

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

Trustees’ Annual Report for the period

From 1/6/2023 Period start date To 31/5/2024 Period end date

Charity name: HaemSTAR: Haematology Specialist Training, Audit and Research

Charity registration number: 1199224

Objectives and Activities

	SORP reference
Summary of the purposes of the charity as set out in its governing document	Para 1.17	To protect and preserve the health of patients suffering from haematological conditions by: a) the promotion of clinical research into Non- Malignant Haematology in the United Kingdom, the causes, prevention and treatment of haematological conditions on terms that the results of such research will be published. b) the advancement of education and training of junior doctors and haematologists to give them the skills to become the chief and principal investigators of the future.'
Summary of the main activities in relation to those purposes for the public benefit, in particular, the activities, projects or services identified in the accounts.	Para 1.17 and 1.19	During 1/6/23 to 31/5/24 we conceived, developed, ran, supported and/or wrote up eighteen projects. All of these projects further our charitable objects because 1) they all require project management (which is used to train junior doctors and haematologists in how to be researchers and principal investigators) and 2) they ultimately result in the publication of research findings that benefit patients. Projects take several years to complete from the time of inception. Activities completed 1/6/23 to 31/4/23 are highlighted inred text. ITP Post COVID19 Vaccine • Type of study:Retrospective Observational Study. • Topic:Timing of onset, clinical characteristics, response to treatment and outcomes of patients with ITP developing following COVID19 vaccination. • HaemSTAR role:Conceived and developed by Dr Quentin Hill (Leeds). Run and promoted by the ITP Forum and HaemSTAR. Data management provided by PHE. Funded by PHE. • Size of study:Data collection completed in 2022. • Size of Study:No results available as study yet to publish. • Main outcomes:Data analysis ongoing. • Outputs:yet to publish. ConNeCT: • Type of study:Prospective Observational Study. • Topic:Neurological, cognitive and neuropsychiatric complications of TTP.

•	HaemSTAR role:Conceived and developed	HaemSTAR role:Conceived and developed
	by Dr Tina Dutt and Dr Rebecca Shaw
	(Liverpool). Run and promoted by the
	University of Liverpool and HaemSTAR. Data
	management provided by University of
	Liverpool. Funded by the Bayer Haemophilia
	Awards Programme.
•	Size of study:211 patients and 50 healthy
	volunteers recruited. Patient recruitment
	completed Feb 2024. Data collection ongoing
	(planned completion Q1 2025).
•	Main outcomes:Interim analysis ongoing,
	likely complete Q1 2026.
•	Outputs:Yet to finish data collection
A2PLS (Anticoagulation in Antiphospholipid
Syndrome):
•	Type of study:Retrospective National Audit.
•	Topic:Compliance with BSH guidelines on
	management of antiphospholipid syndrome
	(APS).
•	HaemSTAR role:Conceived by Dr Deepa
	Arachchillage and Dr Christina Crossette-
	Thambiah (Imperial College). Developed and
	run in collaboration HaemSTAR. Data
	management provided by Imperial College.
	Funded by Bayer AG.
•	Size of study:Recruited 499 patients (Target
	500)
•	Main outcomes:
	`o` Overall: 69% of patients
	anticoagulated with warfarin, 17%
	DOAC, 6% other, 8% not
	anticoagulated.
	`o` Triple Pos: 80% on warfarin. 10%
	DOACs.
	`o` Of those with arterial thrombosis:
	VKA 71%, DOAC 9%, other 19.6%.
	`o` Overall: 39% thrombosis recurrence
	over 10 years (Arterial recurrence
	more likely than venous). Triple vs
	dual vs single positive disease not
	predictive of recurrence
	`o` LAC most predictive marker of
	recurrence
•	Outputs:Oral Presention at American Society
	of Hematology Annual Congress (New
	Orleans) Dec 2022Manuscript in preparation,
	delayed due to some unforeseen devastating
	personal circumstances within the study
	steering group.
BAT-X (Bleeding Assessment Tool in patients with
X-linked agammaglobulinaemia [XLA]):
•	Type of study:Prospective Observational
	Study.
•	Topic:To establish whether patients with XLA
	have increased bleeding.
•	HaemSTAR role:Conceived, developed and
	run by Dr Pip Nicolson and Dr Chris Smith
	(Birmingham) and HaemSTAR. Data
	management provided by University of
	Birmingham. Funded by the British Heart
	Foundation (BHF).
•	Size of study:Recruited 42 patients
•	Main outcomes:Median ISTH-BAT Score	of	1
	(IQR 0-4). 14 participants had scores ≥ 4. Two
	of these had colitis, 3 patients were on
	antiplatelets / anticoagulants / NSAIDs.
•	Outputs:Manuscript in preparation
2SR (Two-Sample Rule Survey)
•	Type of study:Healthcare Practitioner
	Questionnaire

•	Topic:to establish attitudes towards and
	compliance with two (historic) sample rule in
	blood transfusion.
•	HaemSTAR role:Conceived by Dr Lorna Cain
	(Birmingham) and Dr Suzy Morton
	(Birmingham, NHSBT). Developed with the
	help of HaemSTAR. Data management
	provided by NHSBT. Funded by NHSBT.
•	Size of study:209 responses across 22
	hospitals.
•	Main outcomes:96% aware of 2 sample rule
	in their hospital. 57% understand what the rule
	is. 55% understand the rationale for the rule.
	60% admitted to going against the rule on
	more than one occasion. Non-compliant
	behaviour not associated with 2SR training or
	seniority.
•	Outputs:Oral Presention at BSH ASM 2023.
	Manuscript in preparation.
HaemSTAR RAPIDO (A ‘Flash-Mob’ UK national
audit of the use of Reversal Agents in Patients
antIcoagulated with Direct Oral anticoagulants)
•	Type of study:Retrospective National Audit.
•	Topic:Compliance with BSH guidelines for the
	use of reversal agents in patients with major
	haemorrhage who are taking direct oral
	anticoagulants (DOACs).
•	HaemSTAR role:Conceived and developed
	by Dr Richard Buka (Stoke) and HaemSTAR.
	Run by HaemSTAR. Data management
	provided by BiCOPS. Funded by AstraZeneca
	and the Dudley Leukaemia Unit Appear Fund.
•	Size of study:2265 patients.
•	Main outcomes:875 patients had GI
	haemorrhage, 1012 had ICH. Median age 81
	years. Median time from bleed onset to
	reversal: 6.5 hours. Median time from last dose
	of anticoagulation to reversal: 16.0 hours. 1001
	of 1253 non-ICH bleeds fulfilled criteria for
	major hemorrhage. Propensity score-matched
	analysis of 494 patients with GI haemorrhage:
	outcomes similar for andexanet alfa and four
	factor prothrombin complex concentrate.
	Incidence of stroke was significantly higher
	with andexanet alfa.
•	Outputs:Poster presentation at ASH Annual
	Congress 2024 and BSHT Annual Conference
	2025.Manuscripts in preparation.
MOM-ITP: Audit of management of neonatal ITP
•	Type of study:Prospective National Audit
•	Topic:Compliance with international
	consensus guidelines on management of
	pregnant women with ITP and neonatal ITP.
•	HaemSTAR role:Conceived and developed
	by dr Nick Fordham (Evelina Children’s
	Hospital) and Dr Olga Tsiamita (Barts and
	HaemSTAR). Run by HaemSTAR. Data
	Managemetn by HaemSTAR. Funded by
	Grifols.
•	Size of study:Target 100 patients.
	Recruitment ongoing (completion planned Q4
	2025)
•	Main outcomes:data collection ongoing
•	Outputs:data collection ongoing
TXA for HMB in acute VTE
Tranexamic acid is an effective antifibrinolytic drug that
can reduce heavy menstrual bleeding. Despite excellent
safety data showing negligible increased risk of
thrombosis across millions of patient years, its use in
women	with heavy menstrual bleeding who have a
recent venous thromboembolic event remains
controversial. The goal of this project is to work towards
a pilot Randomised Control Trial.

•	Type of study:UK Clinician Survey
•	Topic:Clinical attitudes and practice towards
	use of tranexamic acid in female patients with
	menorrhagia who have previously experienced
	venous thromboembolism.
•	HaemSTAR role:Conceived and developed
	by Dr Eman Hassan (Birmingham and
	HaemSTAR). Distributed by HaemSTAR. Data
	analysis by Dr Hassan. Funding: nil.
•	Size of study:102 respondents.
•	Main outcomes:Apixaban preferred
	anticoagulant for patients with HMB. Wide
	variation in practice re timing of TxA use; 35%
	prescribed it any time following initiation of
	anticoagulation, 12% delayed its use for 3
	months; 8% would never give it. 47% of
	respondents advise to discontinue COCP
	following VTE (whilst treated with
	anticoagulants). 63% of respondents willing to
	participate in a study of TxA ≤ 4 weeks
	following VTE.
•	Outputs:Manuscript in preparation.
•	Type of study: Randomised Controlled Trial
•	Topic:Management of HMB in patients with
	VTE on anticoagulation.
•	HaemSTAR role:conceived and developed by
	Dr Eman Hassan (Birmingham and
	HaemSTAR) and Dr Gill Lowe (Birmingham
	and UK-TReN).
•	Progress:PICO submitted to UK NIHR HTA.
	Outcome awaited.
MATRON (Maternal Audit on ThRombolysis
Outcome and DecisioN)
•	Type of study:UK Clinician Survey &
	Retrospective Audit
•	Topic:The use of thrombolysis for pregnant
	women with venous thromboembolism.
•	Size of study:Survey with 70 responses.
	Target audit responses of 200 patients
	(completion Q2 2025).
•	HaemSTAR Role:Conceived and developed
	by Dr Giulia Simini (Royal London &
	HaemSTAR). Run by HaemSTAR. Data
	management by HaemSTAR.
•	Main outcomes:Survey: CDT available to
	74%, Surgical thrombectomy to 62% and
	ECMO to 52% of respondents. Only 50% of
	sites had specific guidelines on CDT and 17%
	had no guidelines on managing pregnancy
	associated PE. 38% had received specific
	training on pregnancy-associated PE. 22% had
	had training in systemic thrombolysis. 46% did
	not have access to PERT with geographic
	inconsistency. Audit in planning stages.
•	Outputs:Survey manuscript in preparation.
VAMP:	Venesection vs Active Monitoring in
Secondary Polycythaemia
•	Type of study:International clinician survey,
	retrospective audit and then prospective
	clinical trial.
•	Topic:Venesection in patients with idiopathic
	and secondary erythrocytosis
•	Size of study:Survey with 123 responses (90
	senior clinicians). Audit with 206 patients.
	Prospective study in development.
•	HaemSTAR Role:Conceived and developed
	by Dr Richard Buka, Dr Bernard Maybury and
	Dr Pip Nicolson (Birmingham & HaemSTAR),
	Run by HaemSTAR, Data management by
	HaemSTAR.
•	Main outcomes:

`o` Survey: minority venesect routinely,
2/3 will venesect in specific
circumstances; 1/3 never venesect.
More likely to venesect if previous
thrombosis or if headache or visual
disburbance. Majority use Hct
threshold of 0.55 but some use 0.6
and most have Hct target of <0.55
but some use <0.52. 85% willing to
consider entering patients into a trial.
`o` Audit: 2360 patients screened, 206
eligible. 27% no EPO done. Minority
have RCM scan done. Most given
appropriate lifestyle advice. 60%
never venesected. 29% of those
venesected have no target Hct
documented. Mean Hct reduces prior
to diagnosis and further reduces
regardless of venesection. 5 year
thrombosis rate 12% regardless of
venesection vs no venesection or
whether polycythaemia resolves.
Cancer and prior unprovoked VTE
are the only factors to predict
subsequent thrombosis.
• Outputs:Audit poster presentation at BSH
2024. Survey and Audit: manuscript in
preparation.
In set up:
Apixaban thrombo-prophylaxis in multiple myeloma
It is recommended that multiple myeloma patients
treated with IMIDs such as thalidomide and lenalidomide
be offered prophylactic anticoagulation due to the high
risk of VTE. We understand that practice in the UK has
shifted considerably and despite a lack of evidence,
clinicians now favour the use of oral factor anti-Xa
inhibitors, often apixaban, for this purpose. The aim of
this project is to perform a retrospective, observational
study to document thrombosis and bleeding outcomes in
patients who receive this treatment compared to those
who receive low molecular weight heparin.
• Progress:Awaiting outcome of Myeloma UK
grant application (as of 31/5/24)
Anticoagulation at the end of life
A survey is to gather data from secondary care clinicians
in the UK on their management of anticoagulation in
patients at the end of life.
Perioperative management of Haemophilia B
‘FIX-Surg’
The primary objectives of the project are to audit the
haemostatic management of patients with haemophilia B
who are undergoing surgery against international
guidelines (Srivastava et al., 2020).
An Epidemiological Survey of Morbidity and
Mortalityin Patients Over the Age of 35 With
Thalassaemia (Transfusion Dependent and Non-
Transfusion Dependent) in England: SUMMIT
Thalassaemia has historically been a severely life
limiting disease with significant comorbid complications
from an early age. As treatments, monitoring and
awareness of this condition improve, so does quality of
life and life expectancy. This study aims to assess
whether patients over the age of 35 with thalassaemia
are monitored in keeping with national guidelines, and to
build a picture of the co-morbidities affecting patients
with both transfusion and non-transfusion dependent
thalassaemia over the age of 35 in the United Kingdom.
FUNDING AWARDS
From the ISTH Legacy Fund we were able to fund the
conference attendances (see website for awardees).

		Application for award through competitive application with award by grant panel. Part of the ISTH Legacy Fund was to promote collaboration with LMIC (Nigeria) and help them develop their own trainee research network. In collaboration with NSHBT (Nigerian Society for Haematology and Blood Transfusion) they have founded HaemRYNE. Funds go towards infrastructure development and travel costs to promote educational visits within Nigeria and to UK. CONFERENCE In association with Hartley Taylor and the Post ISTH/ASH UK Update meeting we hosted a HaemSTAR Update day on 5/2/24 at Austin Court in Birmingham. This comprised updates and results on current HaemSTAR projects, plenary talks from experts including reflections on clinical/academic careers, management of HMB, CRISPR-Cas9, rural haematology as well as discussions about the role of the NIHR HTA. Very positive feedback. increased industry engagement from previous year. Increased attendance. Free registration HaemSTAR helped with travel reimbursement to enable attendance as well the time of the invited speakers. DISEASE THEMED WEBINARS Teamed up with ‘The Limbic’ to provide monthly online webinars from KOLs providing thought provoking and educational talks on disparate areas of non-malignant haematology. KOLs are reimbursed for their time. The Limbic reimburse HaemSTAR if attendees fill in feedback surveys. PODCAST Received funding from Sobi to purchase equipment and fund external agency to provide sound engineering expertise. Monthly journal club podcast on latest papers in non-malignant haematology. Includes author interviews and discussion with experts. BSH CONFERENCE SESSION HaemSTAR now has a session at BSH (in association with UK-TReN) in the form of Dragon’s Den. HaemSTAR funded the prizes in this session.
Statement confirming whether the trustees have had regard to the guidance issued by the Charity Commission on public benefit	Para 1.18	N/A – not relevant to our charitable purposes

Additional information (optional) You may choose to include further statements where relevant about:

SORP reference N/A Para 1.38 Policy on grant making N/A Para 1.38 Policy on social investment including program related investment N/A Para 1.38 Contribution made by volunteers

N/A

Other

Achievements and Performance

	SORP reference
Summary of the main achievements of the charity, identifying the difference the charity’s work has made to the circumstances of its beneficiaries and any wider benefits to society as a whole.	Para 1.20	FUNDING Received the following grants: - Legacy fund from 2022 ISTH conference in London (see above): £28,810. - Podcast support (unrestricted educational grant) from Sobi: £19,200 - Administrative support (unrestricted grant) from Takeda: £5,000 PUBLICATIONS Nicolson PLR, Belete M, Hawes R, Fowler N, Toh CH. Alternative routes into clinical research: a guide for early career doctors. BMJ. 2024;385:e076414.

Additional information (optional) You may choose to include further statements where relevant about:


Achievements against objectives set	Para 1.41
Performance of fundraising activities against objectives set	Para 1.41
Investment performance against objectives	Para 1.41
Other

Financial Review

Financial Review
Review of the charity’s financial position at the end of the period	Para 1.21	Amount held at start of reporting period: £80,693 Income from all sources (including interest): £54,928 All spending: £39,541 Amount held at the end of the reporting period: £96,081
Statement explaining the policy for holding reserves stating why they are held	Para 1.22	Cash in bank at 31/5/24 was £69,598 in unrestricted funds and £26,492 in restricted funds for ISTH Legacy fund spending committed spending for 2024-25 comprises website hosting fees of approximately £350, podcast hosting fees of £200, accountancy fees of ~£150 and administration costs (paid for the time of our administrator) of ~£3000. This is all covered by the administrative grant of £5000 from Takeda and does not represent a financial risk. We also aim to apply for additional sponsorship of the podcast for when the Sobi sponsorship ends in 2025. In 2023-24 we expanded our ability to fund registrars to attend conferences. £19,200 of this comes from the ISTH Legacy fund and we are able to use this until 2026. It is unlikely that costs will exceed this figure. The educational webinars are a source of an approximately £1200 annual cost. This is voluntary however and can be stopped if there are insufficient funds. There is an approximate £30,000 cost still associated with RAPIDO that is waiting to be paid to the University of Birmingham but this is covered by the Astra Zeneca grant from last year. The HaemSTAR Update Day is now a recurring event but this is organised through Hartley Taylor and they secure industry support for the meeting. The only HaemSTAR costs are voluntary and will not go ahead if there are insufficient funds. All the projects currently active are fully funded. However we would like to run unfunded projects by using money underspent from other projects and also pump prime our pipeline by employing a project/data manager through the University of Birmingham at a cost of approximately £70,000 per year. This is not yet feasible and will not go ahead unless there are sufficient funds. The funding for this will be reviewed on an annual basis and no commitments beyond 1 year will be made to ensure there is no financial risk to the charity.
Amount of reserves held	Para 1.22	£0
Reasons for holding zero reserves	Para 1.22	We do not have a reserve policy.
Details of fund materially in deficit	Para 1.24	N/A
Explanation of any uncertainties about the charity continuing as a going concern	Para 1.23	Nil uncertainties. N/A

Additional information (optional) You may choose to include further statements where relevant about: The charity’s principal sources of funds (including Para 1.47 any fundraising)

Investment policy and objectives including any social investment policy adopted	Para 1.46
A description of the principal risks facing the charity	Para 1.46
Other

Structure, Governance and Management

Description of charity’s trusts:		Nil
Type of governing document (trust deed, royal charter)	Para 1.25	Constitution
How is the charity constituted? (e.g unincorporated association, CIO)	Para 1.25	Unincorporated Association
Trustee selection methods including details of any constitutional provisions e.g. election to post or name of any person or body entitled to appoint one or more trustees	Para 1.25	Nil.

Additional information (optional) You may choose to include further statements where relevant about:

Policies and procedures adopted for the induction Para 1.51 and training of trustees The charity’s organisational structure and any wider Para 1.51 network with which the charity works Relationship with any related Para 1.51 parties Other

Reference and Administrative details

Charity name	HaemSTAR: Haematology Specialist Training, Audit and Research
Other name the charity uses	HaemSTAR
Registered charity number	1199224
Charity’s principal address	Office 129, Institute of Biomedical Research Edgbaston Birmingham B15 2TT

Names of the charity trustees who manage the charity

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Trustee name	Office (if any)	Dates acted if not for whole year	Name of person (or body) entitled to appoint trustee (if any)
	PhillipLR Nicolson	President
	Richard J Buka	Chair
	Andrew J Doyle
	EmilyMillen
	Tom Bull

– Corporate trustees names of the directors at the date the report was approved

Director name

Name of trustees holding title to property belonging to the charity

Trustee name Dates acted if not for whole year

Funds held as custodian trustees on behalf of others

Description of the assets Nil held in this capacity Name and objects of the N/A charity on whose behalf the assets are held and how this falls within the custodian charity’s objects Details of arrangements for N/A safe custody and segregation of such assets from the charity’s own assets

Additional information (optional)

Names and addresses of advisers (Optional information)

Type of Name Address adviser

Name of chief executive or names of senior staff members (Optional information)

Exemptions from disclosure

Reason for non-disclosure of key personnel details

N/A

Other optional information

Declarations

The trustees declare that they have approved the trustees’ report above.

Signed on behalf of the charity’s trustees

Signature(s) Full name(s) Dr Phillip LR Nicolson Position (eg Secretary, President Chair, etc) Date 21/3/2025

	HaemSTAR: Haematology Specialty Training Audit and Research	HaemSTAR: Haematology Specialty Training Audit and Research	HaemSTAR: Haematology Specialty Training Audit and Research	1199224	CC16a
	Receipts and payments accounts
	For the period from	01/06/2023	To	31/05/2024

Section A Receipts and payments
A1 Receipts	Unrestricted funds to the nearest £	Restricted funds to the nearest £	Endowment funds to the nearest £	Total funds to the nearest £	Last year to the nearest £
ISTH LegacyFund Award 30/6/2023		28 810	-	28 810	35 200
Sobi Podcast Sponsorship 12/12/2023 (inv 20231129 Sobi Podcasts)	19 200	-	-	19 200	17 600
35-daySavings Interest(29/12/23)	103			103
Takeda Non-specificgrant 9/1/24	5 000	-	-	5 000	-
35-daySavings Interest(31/01/24)	197			197
35-daySavings Interest(29/02/24)	174			174
Business Reserve Interest 29/2/24	1			1
35-daySavings Interest(28/3/24)	168			168
Business Reserve Interest 28/3/24	11			11
95-daySavings Interest(28/3/24)	32			32
Business Reserve Interest 30/4/24	13			13
35-daySavings Interest(30/4/24)	199			199
95-daySavings Interest(30/4/24)	38			38
Business Reserve Interest 31/5/24	12			12
35-daySavings Interest(31/5/24)	185			185
95-daySavings Interest(31/5/24)	36			36
PipNicolson(Charitable Donation)2/4/24	750	-	-	750	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
	-	-	-	-	-
*Sub total*(Gross income for AR)	26 118	28 810	-	54 928	52 800
A2 Asset and investment sales, (see table).
	-	-	-	-
	-	-	-	-	-
*Sub total*	-	-	-	-	-
*Total receipts* A3 Payments
	26 118	28 810	-	54 928	52 800

Squarespace(Web domain)6/6/2023	19	-	-	19	23
University of Birmingham (RAPIDO 1 inv 71049181)16/6/2023	20 000	-	-	20 000	268
Squarespace(Web domain)6/7/2023	19	-	-	19	2 786
Squarespace(Web domain)6/8/2023	19	-	-	19	240
RCPath (Podcast CPD Accreditation) 14/8/2023	250	-	-	250	543
Squarespace(Web domain)6/9/2023	19	-	-	19	45
Rich Buka (Ableton Software for Podcast) 12/9/2023	129	-	-	129	155
University of Birmingham (RAPIDO 2 inv 71345158)6/10/2023	10 000	-	-	10 000	189
Squarespace(Web domain)6/10/2023	19			19	82
Amazon (Ian Roberts, Limbic Webinar Thankyou Payment 6/10/2023)	100			100	338
Squarespace(Web domain)6/11/2023	19			19	19
Amazon (Noemi Roy, Limbic Webinar Thankyou Payment 27/11/2023)	100			100	19
Squarespace(Web domain)6/12/2023	19			19	19
Squarespace(Web domain)8/1/2024	19			19	26
Helen Apperley (Jun 23-Jan 24 Admin support,90 hrs at £15ph)15/1/24	1 350			1 350	250
Maryam Subhan (ISTH Legacy Fund, 15/1/24) Acast (Podcast hosting annual fee, 15/1/24) Amazon (audio equipment for podcast: XLR microphone cable) 24/1/24 Amazon (Audio equipment for podcast: condenser microphone, pop filter, mic stand,25/1/24)		1 418		1 418	19
	145			145
	11			11
	382			382
Amazon (Mark Thomas & Sutesh Sivapalaratnam, Limbic Webinar Thank you Payments x2 29/1/24)	200			200
Squarespace(Web domain)6/2/2024	19			19
Amazon (Angela Weyland HaemSTAR update day speaker thank you payment 20/2/24)	150			150
Amazon (Dan Hart, A Rutherford, Sophie Evans, M Badat. HaemSTAR update day speaker thank you payments x4 26/2/24)	400			400
Squarespace(Web domain)26/2/2024	3			3
Squarespace(Web domain)6/3/24	29			29
Olga Tsiamita (HaemSTAR update day travel. 13/3/24) J Schofield (HaemSTAR update day travel. 13/3/24) Julia Wolf (HaemSTAR update day travel. 13/3/24) Stephen Hibbs (HaemSTAR update day travel. 13/3/24) Helen Apperley (postage reimbursement. 13/3/24) Giulia Simini (HaemSTAR update day travel. 13/3/24) Ethan Troy-Barnes (HaemSTAR update day travel. 13/3/24) Catrin Cox (BSH Travel 13/3/24) Christina Crossette-Thambiah (BSH Travel 13/3/24) Joe Apperley (Podcast editing x2 episodes) 26/3/24 Amazon (Tom Bullock, Limbic webinar thankyoupayment)	177			177
	126			126
	174			174
	57			57
	14			14
	147			147
	134			134
	120			120
	120			120
	680			680
	100			100
Squarespace(Web domain)7/3/2024	29			29

CCXX R1 accounts (SS)

John Chadwick (ISTH Legacy Fund) 5/4/2024		750		750
Willows Accountancy (Preparation of Annual Accounts)5/4/2024	120			120
Squarespace(Web domain)8/4/2024	29			29
BACARO, Liverpool (BSH Reps Meal) 30/4/24	420			420
Amazon (Richard Riley & Bernard Laemmle, Limbic Webinar Thank you Payments x2 20/05/2024)	200			200
Gill Lowe (BSH Session Prize reimbursement, 28/5/24) Elena Torre (ISTH Legacy Fund, BSH 28/5/24) Richard Buka (BSH Hotel/Travel, 28/5/24) Lottie Hickman (BSH Hotel/Travel, 28/5/24) Yen Huan Yeo (ISTH Legacy Fund, BSHT 28/5/24) **Sub total **	100			100
		500		500
	107			107
	198			198
		400		400
		-	-	-	-
	36 473	3 068	-	39 541	5 022

A4 Asset and investment purchases, (see table)
	-	-	-	-
	-	-	-	-
*Sub total* *Total payments* *Net of receipts/(payments)* A5 Transfers between funds A6 Cash funds last year end *Cash funds this year end*	-	-	-	-	-

	36 473	3 068	-	39 541	5 022

	- 10 355	25 742	-	15 388	47 778
	-	-	-	-	-
	80 693	-	-	80 693	-
	70 338	25 742	-	96 081	47 778

Section B Statement of assets and liabilities at the end of the period	Section B Statement of assets and liabilities at the end of the period	Section B Statement of assets and liabilities at the end of the period	Section B Statement of assets and liabilities at the end of the period
Categories Signed by one or two trustees on behalf of all the trustees B5 Liabilities B3 Investment assets B2 Other monetary assets B4 Assets retained for the charity’s own use B1 Cash funds	Details	Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
	Money in bank account (31.5.24)	96 081	-	-
		-	-	-
		-	-	-
	*Total cash funds* (agree balances with receipts and payments account(s)) Details	96 081	-	-
		Agreement Error	Agreement Error	OK
		Unrestricted funds to nearest £	Restricted funds to nearest £	Endowment funds to nearest £
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
		-	-	-
	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
			-	-
			-	-
			-	-
			-	-
			-	-
	Details	Fund to which asset belongs	Cost (optional)	Current value (optional)
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
			-	-
	Details	Fund to which liability relates	Amount due (optional)	When due (optional)
			-
			-
			-
			-
			-
	Signature	Print	Name	Date of approval

CCXX R2 accounts (SS)

CHARITY COMMISSION FOR ENGLAND AND WALES Independent examiner's report on the accounts Se¢tlon A Independent Examiner's Report Reportto the tru8teès Haemstar.. Haematology Speciality Training Audit and Research On accounts for the year ended 3110512024 Charity no Ilf any) 1199224 Set out on pages I report lo the Iruslees on my examination of the account5 of the above charity I'lhe Trusf'l for the year ended 31 May 2024. Re8pon85bllitle8 and ba818 of report As the charity's Iruslees, you are responsible lor the preparation of the a¢counls in accordance with the requirements of the Charities Act 2011 I'the Acl'l I report In respect of my examination of the Trust's accounts carried out under section 145 of the 2011 Act and in carrying out my examination, I have followed all the applicable Directions given by the Ch8rily Ccmmis8ion under section 14515llbl of the Act. Independent I have completed my examination. I confirm that no material matters have examlner's statement come lo my attention in connection with the examination which gives me cause lo believe that in, any material respe¢l'. the accounting records were not kept in accordance wth section 130 of the Charities Act.. or the accounts did not accord with the accounting records., or the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a 'lrue and fair, view which is not a matter considered as part of an independent examination. I have no Concerns and have come across no other matters in connection with the examination to which allenlion should be drawn in this report in order to enable a proper understanding of the accounts to be reached. Pl88s6 delete the w04S in the bCkel5 if Ihgy do not apply. Slgned: Date: 18 March 2025 Name: Mark Fellows (Willows Accountaney Lldl Rglevant professlonal quallficationls) or body lif any): Fellow Member of Association of Accounting Technicians Address: 172 Watling Street, Bridglown, Staffordshire, WS1108D IER Oct 2018

Section B Disclosuro Only complete If the examiner needs to highlight material matters of concErn (see CC32, Independent examination of charity aecounts". directions and guidance for examiners). Glve here brlef detall8 of any Items that the examlnerwl8he8 to disc108e. IER Oct 2018